
|Articles|August 27, 2008
FDA speeds up review of Droxidopa
The drug is marketed in Japan to treat low blood pressure.
Advertisement
The Food and Drug Administration has given fast-track designation to Droxidopa, which is marketed in Japan to treat low blood pressure. Such a designation is reserved for drugs that treat serious conditions for which there is an unmet need. The maker of the drug, Chelsea Therapeutics International, says it plans to seek marketing approval for Droxidopa after completing clinical trials this year.
To see more Daily News articles,
To go to the Drug Topics homepage,
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Targeted Coordination Is Crucial in Boosting Pneumococcal Vaccine Coverage
2
CoronaVac Improves Outcomes of COVID-19 for Patients With Schizophrenia
3
Reducing HIV Stigma Can Improve Patient Care, Provider Connectivity
4
Harps Food Train Pharmacists to Confidently Prescribe Birth Control
5
















































































































